Drugs in Dev. Obstetrics/Gynecology (Women’s Health)
Phase IV
Switzerland 
Lead Product(s) : Follitropin Delta
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rekovelle (follitropin delta) is a follicle-stimulating hormone made from recombinant human DNA that is used to promote follicular development in females with ovarian failure, reproduction and fertility.
Product Name : Rekovelle
Product Type : Hormone
Upfront Cash : Inapplicable
March 14, 2023
Lead Product(s) : Follitropin Delta
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Menotropins
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : MEGASET-HR (high responder) study met its primary non-inferiority endpoint, with Menopur-treated patients experiencing a 35.5% ongoing pregnancy rate (OPR) per cycle start after a fresh transfer, compared to 30.7% for rFSH-treated patients
Product Name : Menopur
Product Type : Hormone
Upfront Cash : Inapplicable
May 14, 2020
Lead Product(s) : Menotropins
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Menotropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Menopur
Product Type : Hormone
Upfront Cash : Inapplicable
September 18, 2015
Lead Product(s) : Menotropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urofollitropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FSH in GnRH-AntagoniST Controlled Ovarian Hyperstimulation Cycles (FAST)
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
October 25, 2013
Lead Product(s) : Urofollitropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Urofollitropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 16, 2011
Lead Product(s) : Urofollitropin
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Menotropins
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Ferring Arzneimittel GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Progesterone Serum Levels in Subfertile Female Patients Undergoing in Vitro Fertilisation (IVF)
Details : Undisclosed
Product Name : Menogon HP
Product Type : Protein
Upfront Cash : Inapplicable
October 21, 2010
Lead Product(s) : Menotropins
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Ferring Arzneimittel GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 27, 2010
Lead Product(s) : Tranexamic Acid
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Phase IV
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
